Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Review of EMPA-REG OUTCOME trial (n=7020) found, that when anaysing total (first plus recurrent) cardiovascular events, empagliflozin reduced the risk of major adverse cardiovascular events vs placebo (RR 0.78, 95%CI 0.67-0.91; 12.88 events prevented per 1000 patient years).

The Lancet Diabetes & Endocrinology